Log In Get Started
Press Releases July 22, 2026 05:00 PM

Brown & Brown, Inc. announces quarterly cash dividend

Brown & Brown Declares Quarterly Cash Dividend of $0.165 per Share

By Priya Menon
Share
Twitter Reddit Facebook LinkedIn
BRO

Brown & Brown, Inc., a leading insurance brokerage firm, announced a quarterly cash dividend of $0.165 per share payable to shareholders on August 19, 2026. The dividend reflects the company's ongoing commitment to returning value to shareholders.

Brown & Brown, Inc. announces quarterly cash dividend
BRO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Brown & Brown declared a regular quarterly cash dividend of $0.165 per share.
  • Dividend payable on August 19, 2026, to shareholders of record on August 12, 2026.
  • Company operates over 700 locations globally with approximately 23,000 employees, serving as a major player in the insurance brokerage sector.

DAYTONA BEACH, Fla., July 22, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE: BRO) announces that the board of directors has declared a regular quarterly cash dividend of $0.165 per share. The dividend is payable on August 19, 2026, to shareholders of record on August 12, 2026.

About Brown & Brown, Inc.

Brown & Brown, Inc. (NYSE: BRO) is a leading insurance brokerage firm delivering comprehensive and customized insurance solutions and specialization since 1939. With a global presence spanning 700+ locations and a team of approximately 23,000 professionals, we are dedicated to delivering scalable, innovative strategies for our customers at every step of their growth journey. Learn more at BBrown.com.

For more information:

R. Andrew Watts
Chief Financial Officer
(386) 239-5770


Risks

  • Dividend amounts are subject to change based on company performance and market conditions.
  • Economic downturns or adverse insurance market conditions could impact Brown & Brown's earnings and future dividends.
  • Regulatory changes affecting the insurance industry could pose uncertainties for business operations.

More from Press Releases

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026 Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Sep 4, 2026